Understanding treatment effects in adult patients with status epilepticus
Official title: Status Epilepticus Population Study (STEPS)
Run by University Hospital, Basel, Switzerland · NCT04204863 · Data updated 2026-11-12
This study looks at how different treatments for adults with status epilepticus can improve their outcomes by tracking patient data from two hospitals.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 2 sites (Aarau and 1 other locations) |
| Status | Recruiting |
| Started | April 19, 2019 |
| Main results expected | December 2050 |
| Study ends | December 2050 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT04204863 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult patients aged 18 and older who have been diagnosed with status epilepticus and treated at the participating hospitals.
✕Probably not a fit
Patients younger than 18 years or those with repetitive seizures not qualifying for status epilepticus may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational multicenter cohort study aims to enhance knowledge about the treatment of adult patients experiencing status epilepticus (SE). By collecting patient data from the University Hospital of Basel and the Cantonal Hospital Aarau, the study will analyze the impact of treatment adaptations based on outcome prediction models and risk stratification. The focus is on monitoring, detecting, preventing, and managing complications associated with SE to improve patient outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients suffering from status epilepticus.
How similar studies have gone: While this study focuses on observational data collection, similar studies have shown promise in improving outcomes for patients with status epilepticus through enhanced treatment strategies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (i.e., patients ≥18 years of age) with diagnosed SE between 2005 and 2023 who have been treated at the University Hospital of Basel or the Cantonal Hospital Aarau. Exclusion Criteria: * Patients younger than 18 years. * Patients with repetitive epileptic seizures not qualifying for SE. * Patients with documented refusal of the general consent.
Where it's running
-
Cantonal Hospital Aarau (KSA)
Aarau, Switzerland Recruiting -
Clinic for Intensive Care Medicine, University Hospital Basel
Basel, Switzerland Recruiting
Study contacts
- Principal investigator: Raoul Sutter, PD Dr. med — Clinic for Intensive Care Medicine, University Hospital Basel
- Study coordinator: Raoul Sutter, PD Dr. med
- Email: Raoul.Sutter@usb.ch
- Phone: +41 61 265 25 25
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SPN-817 for adults with treatment-resistant epilepsy
We will try SPN-817 to see if it is safe and tolerable for adults whose seizures haven't responded to standard treatments.
-
Analyzing brain imaging biomarkers in patients with cerebral cavernous malformation-related epilepsy
This study is trying to see if brain scans can help find signs of iron buildup in people with cerebral cavernous malformation and epilepsy, which could improve how we manage their condition.
-
Single dose ayahuasca in adults with psychogenic non-epileptic seizures
This open-label study tests whether a single dose of ayahuasca is safe and what effects it has in adults with psychogenic non-epileptic seizures who are under care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.